Kyowa Hakko Enters Antibody Space With Alnylam RNAi RSV Therapy
This article was originally published in PharmAsia News
Executive Summary
TOKYO - In its quest to expand into the antibody therapy area, Kyowa Hakko Kogyo signed a license contract for marketing Alnylam's respiratory syncytial virus injection drug in Japan and East Asian countries, a Kyowa Hakko spokesman confirmed June 23
You may also be interested in...
RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway
Alnylam has been able to “accomplish a tremendous amount in a fairly short period of time by” partnering with Takeda and Kyowa Hakko Kirin, as well as Roche and Novartis, business development exec says.
RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway
TOKYO - An executive from Massachusetts-based biotech Alnylam says its RNAi alliances with Takeda and Kyowa Hakko Kirin are well underway
RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway
Alnylam has been able to “accomplish a tremendous amount in a fairly short period of time by” partnering with Takeda and Kyowa Hakko Kirin, as well as Roche and Novartis, business development exec says.